{"id":"W2883374837","doi":"10.1200/jco.2016.34.15_suppl.tps4152","title":"POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (g<i>BRCA</i>m).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Clinical endpoint; BRCA mutation; Oncology; Population; Regimen; Cancer; Phases of clinical research; Ovarian cancer; Surgery; Randomized controlled trial; Chemotherapy; Genetics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008519686,0.001384133,0.001410308,0.0003210133,0.0003578259,0.001470725,0.0008952781,0.001370333,0.01223403],"category_scores_gemma":[0.001102766,0.0006716617,0.001250562,0.0003562837,0.001070835,0.00115769,0.0005071394,0.00301147,0.001634499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007773915,"about_ca_system_score_gemma":0.001244122,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005838046,"about_ca_topic_score_gemma":0.001743803,"domain_scores_codex":[0.9997186,0.0001297443,0.00001440467,0.00006043197,0.00002445219,0.00005239671],"domain_scores_gemma":[0.9995523,0.00008440777,0.0001160872,0.00003555994,0.0000222519,0.0001893514],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9467578,0.006886994,0.001156636,0.001306286,0.00064401,0.0001250976,0.0001121672,0.0006017432,0.006379194,0.0004232129,0.003497737,0.03210919],"study_design_scores_gemma":[0.9536232,0.04139979,0.001478415,0.00005101393,0.0001956506,0.00009925429,0.00003261956,0.0003781412,0.0002810418,0.0002799477,0.002167271,0.0000137572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9592242,0.006541611,0.001827397,0.00290983,0.001421816,0.01072883,0.004552606,0.0005443145,0.01224941],"genre_scores_gemma":[0.9604391,0.004006173,0.002622729,0.003779316,0.0004668811,0.01118575,0.005677095,0.00007808871,0.01174485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01223403,"threshold_uncertainty_score":0.04092693,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06732688848700241,"score_gpt":0.4505925390702192,"score_spread":0.3832656505832168,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}